Bug-busting technology kills CRE Klebsiella pneumoniae
BioCote solution found to be effective against fourth major hospital superbug
BioCote has demonstrated that its antimicrobial technology is effective against a fourth serious hospital superbug.
An independently-performed ISO 22196 test demonstrated that BioCote’s bug-busting system eliminates more than 99.9% of the bacterium CRE Klebsiella pneumoniae . These results also demonstrates that resistance to antibiotics in bacteria does not mean resistance to the BioCote technology.
This is the fourth multi-drug resistant bacteria which BioCote has proven effective against.
CRE are a family of bacteria which, over the past decade, have been causing increasing problems in healthcare environments around the world. CRE-related infections most commonly occur among individuals who are hospitalised, critically ill or who require invasive devices such as ventilators. They are dangerous because they are resistant to the group of antibiotics known as carbapenems, which are recognised as being among the most powerful antibiotics.
Richard Hasting, technical director at BioCote, said: “We are always looking for ways in which our antimicrobial technology can solve a problem and support the healthcare industry.
“Multidrug resistant pathogens are extremely worrying for the healthcare industry, and so the results from this test are very encouraging. Alongside good cleaning and disinfection procedures, BioCote’s technology can help control antibiotic resistant bacteria in a healthcare environment. The development of new drugs to combat these infections is still necessary, but BioCote help to minimise the crisis by preventing the spread and survival of bacteria in the first place.”
BioCote technology has already been proven to be effective against a wide range of bacteria and fungi including MRSA, VRE and ESBL.
